Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aclaris Therapeutics

1.44
+0.06004.35%
Post-market: 1.440.00000.00%16:18 EDT
Volume:668.87K
Turnover:945.71K
Market Cap:155.92M
PE:-0.84
High:1.46
Open:1.40
Low:1.37
Close:1.38
Loading ...

Aclaris Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
02 May

Aclaris Therapeutics Names Jesse Hall Chief Medical Officer

MT Newswires Live
·
30 Apr

Aclaris Therapeutics Appoints Jesse Hall, M.d. as Chief Medical Officer

THOMSON REUTERS
·
29 Apr

Press Release: Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Dow Jones
·
29 Apr

Aclaris Gets FDA Clearance for Clinical Trial of Immuno-Inflammatory Treatment

MT Newswires Live
·
22 Apr

Aclaris Therapeutics Shares Rise After FDA Clear ATI-052 for Trial

Dow Jones
·
22 Apr

Aclaris Therapeutics Secures U.S. Food and Drug Administration Ind Clearance for ATI-052, Enabling Advancement of Its Novel Bispecific Anti-Tslp/Il-4R Investigational Antibody

THOMSON REUTERS
·
22 Apr

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

GlobeNewswire
·
22 Apr

Institutional investors in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) see US$21m decrease in market cap last week, although long-term gains have benefitted them.

Simply Wall St.
·
05 Apr

Aclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald

TipRanks
·
19 Mar

Aclaris Therapeutics Initiated at Sector Outperform by Scotiabank

Dow Jones
·
08 Mar

Aclaris Therapeutics initiated with an Outperform at Scotiabank

TIPRANKS
·
07 Mar

Aclaris Therapeutics (NASDAQ:ACRS shareholders incur further losses as stock declines 12% this week, taking three-year losses to 88%

Simply Wall St.
·
06 Mar

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

GlobeNewswire
·
04 Mar

This Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last Year

Simply Wall St.
·
04 Mar

Aclaris Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
04 Mar

BRIEF-Aclaris Therapeutics Files For Mixed Shelf Of Up To $300 Million - SEC Filing

Reuters
·
28 Feb

Aclaris Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Feb

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
27 Feb

Aclaris: Q4 Earnings Snapshot

Associated Press Finance
·
27 Feb